Sugi Predict

Sugi Predict / Targets / DPP9

DPP9

Dipeptidyl peptidase 9 · Q86TI2 · DPP9 on Sugi Atlas →

87,086 patent compounds predicted against DPP9, 41,674 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL294870 SCHEMBL294870 0.54 16/20
SCHEMBL295447 SCHEMBL295447 0.71 15/20
SCHEMBL294677 SCHEMBL294677 0.69 15/20
SCHEMBL294712 SCHEMBL294712 0.68 15/20
Talabostat Talabostat (SCHEMBL393024) 1.00 14/20
SCHEMBL295843 SCHEMBL295843 0.70 14/20
SCHEMBL293795 SCHEMBL293795 0.69 14/20
SCHEMBL294679 SCHEMBL294679 0.68 14/20
SCHEMBL295145 SCHEMBL295145 0.66 14/20
SCHEMBL293981 SCHEMBL293981 0.48 14/20
SCHEMBL293982 SCHEMBL293982 0.48 14/20
SCHEMBL293476 SCHEMBL293476 0.67 13/20
SCHEMBL293256 SCHEMBL293256 0.57 13/20
SCHEMBL294237 SCHEMBL294237 0.55 13/20
SCHEMBL294749 SCHEMBL294749 0.54 13/20
SCHEMBL296101 SCHEMBL296101 0.52 13/20
SCHEMBL295239 SCHEMBL295239 0.52 13/20
SCHEMBL293681 SCHEMBL293681 0.51 13/20
SCHEMBL294717 SCHEMBL294717 0.51 13/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL294373) 0.50 13/20

Clinical trials — most relevant to DPP9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats PHASE4COMPLETED
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes PHASE4UNKNOWN
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients) PHASE4COMPLETED
Incretins in Impaired Fasting Glucose PHASE4COMPLETED
Correlation Between Plasma- and Endothelial DPP-4 Activity PHASE4COMPLETED
The Effects of Neprilysin on Glucagon-like Peptide-1 PHASE4COMPLETED
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4 PHASE4ACTIVE_NOT_RECRUITING
Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI PHASE4WITHDRAWN
Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas PHASE4COMPLETED
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors PHASE4UNKNOWN
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes PHASE3COMPLETED
The Vascular Effects of Vildagliptin in Insulin Resistant Individuals PHASE3COMPLETED
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients PHASE3UNKNOWN
Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients PHASE3ENROLLING_BY_INVITATION
Sitagliptin and Endothelial Dysfunction PHASE3UNKNOWN
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency PHASE2COMPLETED
Mechanisms Underlying Predictors of Success From Obesity Surgery PHASE2WITHDRAWN
Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2. PHASE2COMPLETED
Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy PHASE2COMPLETED
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis PHASE2RECRUITING
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM PHASE1RECRUITING
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals PHASE1COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation nanCOMPLETED
The Incretin Effect in Patients With Kidney Impairment nanCOMPLETED
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects nanUNKNOWN
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients nanCOMPLETED
Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DPP9 binder may also engage these)

ProteinNameSimilarity
Q8BVG4 — 1.000 Q8BVG4 →
A0A2R8QP51 — 0.992 A0A2R8QP51 →
Q80YA7 — 0.977 Q80YA7 →
Q8R146 — 0.976 Q8R146 →
P80227 — 0.975 P80227 →
P19205 — 0.973 P19205 →
P25154 — 0.973 P25154 →
DPP8 Dipeptidyl peptidase 8 0.973 landscape →
P13676 — 0.971 P13676 →
APEH Acylamino-acid-releasing enzyme 0.968 landscape →
Q10MJ1 — 0.966 Q10MJ1 →
Q641Y5 — 0.963 Q641Y5 →
Q14CH1 — 0.963 Q14CH1 →
Q5IH13 — 0.963 Q5IH13 →
E9Q4Z2 — 0.963 E9Q4Z2 →
Q94E75 — 0.963 Q94E75 →
Q6NYU2 — 0.962 Q6NYU2 →
Q5ZKY2 — 0.961 Q5ZKY2 →
Q5ZJV4 — 0.961 Q5ZJV4 →
Q8BGT5 — 0.961 Q8BGT5 →
Q6GM82 — 0.961 Q6GM82 →
Q8VZF3 — 0.961 Q8VZF3 →
CHAF1B Chromatin assembly factor 1 subunit B 0.960 landscape →
Q8N5D0 — 0.960 Q8N5D0 →
PARP4 Protein mono-ADP-ribosyltransferase PARP4 0.960 landscape →
Q90678 — 0.960 Q90678 →
A5PK19 — 0.960 A5PK19 →
Q5R514 — 0.960 Q5R514 →
Q9ER88 — 0.960 Q9ER88 →
P82922 — 0.960 P82922 →